228:
29:
408:
It was discovered at Hanmi; in August 2014 Hanmi exclusively licensed rights in China to the
Chinese company Luye Pharma and in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum.
310:
457:
352:
InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)
324:
542:
344:
394:
65:
41:
147:
207:
383:
510:
475:
Roskoski R (September 2014). "ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors".
412:
As of 2016 Spectrum had started a Phase II trial of poziotinib a second-line treatment for breast cancer.
517:. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services
379:
223:
82:
196:
492:
136:
91:
484:
244:
156:
227:
458:"Hanmi Pharmaceutical to Step Up R&D Investment to Further Develop Core Technologies"
536:
116:
429:
390:
488:
286:
127:
496:
20:
398:
102:
28:
332:
COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C
176:
402:
309:
300:
187:
167:
212:
298:
285:
243:
238:
206:
186:
166:
146:
126:
101:
81:
56:
40:
35:
115:
90:
8:
19:
382:(in South Korea), Luye Pharma (China), and
451:
449:
447:
226:
135:
27:
155:
421:
349:
329:
222:
70:
18:
405:and binds covalently to its targets.
386:(rest of world) for various cancers.
195:
7:
175:
106:
73:1-oxypiperidin-1-yl]prop-2-en-1-one
14:
395:epidermal growth factor receptors
270:
267:
261:
255:
357:Key:LPFWVDIFUFFKJU-UHFFFAOYSA-N
378:) is a drug in development by
276:
249:
1:
559:
489:10.1016/j.phrs.2014.06.001
393:scaffold and inhibits the
389:It is built on an anilino-
239:Chemical and physical data
543:Experimental cancer drugs
340:
320:
61:
26:
477:Pharmacological Research
384:Spectrum Pharmaceuticals
456:Kim M (4 July 2016).
380:Hanmi Pharmaceutical
515:NCI Drug Dictionary
23:
365:
364:
311:Interactive image
208:CompTox Dashboard
16:Chemical compound
550:
527:
526:
524:
522:
507:
501:
500:
472:
466:
465:
453:
442:
441:
439:
437:
426:
313:
293:
278:
272:
269:
263:
257:
251:
231:
230:
216:
214:
199:
179:
159:
139:
119:
109:
108:
94:
31:
24:
22:
558:
557:
553:
552:
551:
549:
548:
547:
533:
532:
531:
530:
520:
518:
509:
508:
504:
474:
473:
469:
455:
454:
445:
435:
433:
428:
427:
423:
418:
361:
358:
353:
348:
347:
336:
333:
328:
327:
316:
291:
281:
275:
266:
260:
254:
234:
210:
202:
182:
162:
142:
122:
105:
97:
77:
74:
69:
68:
52:
17:
12:
11:
5:
556:
554:
546:
545:
535:
534:
529:
528:
502:
467:
443:
420:
419:
417:
414:
363:
362:
360:
359:
356:
354:
351:
343:
342:
341:
338:
337:
335:
334:
331:
323:
322:
321:
318:
317:
315:
314:
306:
304:
296:
295:
289:
283:
282:
279:
273:
264:
258:
252:
247:
241:
240:
236:
235:
233:
232:
224:DTXSID80148853
219:
217:
204:
203:
201:
200:
192:
190:
184:
183:
181:
180:
172:
170:
164:
163:
161:
160:
152:
150:
144:
143:
141:
140:
132:
130:
124:
123:
121:
120:
112:
110:
99:
98:
96:
95:
87:
85:
79:
78:
76:
75:
72:
64:
63:
62:
59:
58:
54:
53:
51:
50:
46:
44:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
555:
544:
541:
540:
538:
516:
512:
506:
503:
498:
494:
490:
486:
482:
478:
471:
468:
463:
462:BusinessKorea
459:
452:
450:
448:
444:
432:. AdisInsight
431:
425:
422:
415:
413:
410:
406:
404:
400:
396:
392:
387:
385:
381:
377:
373:
369:
355:
350:
346:
339:
330:
326:
319:
312:
308:
307:
305:
302:
297:
290:
288:
284:
248:
246:
242:
237:
229:
225:
221:
220:
218:
209:
205:
198:
194:
193:
191:
189:
185:
178:
174:
173:
171:
169:
165:
158:
154:
153:
151:
149:
145:
138:
134:
133:
131:
129:
125:
118:
114:
113:
111:
104:
100:
93:
89:
88:
86:
84:
80:
71:
67:
60:
55:
48:
47:
45:
43:
39:
34:
30:
25:
519:. Retrieved
514:
511:"Poziotinib"
505:
480:
476:
470:
461:
434:. Retrieved
430:"Poziotinib"
424:
411:
407:
388:
375:
371:
367:
366:
197:CHEBI:195559
92:1092364-38-9
49:experimental
42:Legal status
36:Legal status
391:quinazoline
294: g·mol
57:Identifiers
416:References
368:Poziotinib
299:3D model (
287:Molar mass
157:OEI6OOU6IK
128:ChemSpider
83:CAS Number
66:IUPAC name
21:Poziotinib
483:: 42–59.
376:HM781-36B
372:NOV120101
537:Category
521:25 March
497:24928736
436:25 March
399:HER2/neu
137:30687714
117:25127713
245:Formula
103:PubChem
495:
401:, and
397:EGFR,
325:SMILES
292:491.34
177:D12229
403:Her 4
345:InChI
301:JSmol
188:ChEBI
523:2017
493:PMID
438:2017
168:KEGG
148:UNII
485:doi
213:EPA
107:CID
539::
513:.
491:.
481:87
479:.
460:.
446:^
374:,
262:Cl
259:21
253:23
525:.
499:.
487::
464:.
440:.
370:(
303:)
280:3
277:O
274:4
271:N
268:F
265:2
256:H
250:C
215:)
211:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
